Replies to post #123236 on Anavex Life Sciences Corp (AVXL)

[bas2020]

If seizures are reduced within a few weeks after taking the drug, then that is plenty of evidence to suggest efficacy for a disease that has no existing treatment.

[Gernee20]

Blu, I think a lot of what Anavex is predicting for Rett and PK is that their will be noticeable physical improvements in motor function and decrease in seizure frequency, per the preclinical efficacy. I think they learned from the AD trial that the drug is fast acting and delivers results almost immediately. They designed the trials short in duration and it's because Anavex is confident they will be able to determine if the drug is having an effect by the 12 week mark.

[seventhwave]

...3 month trials for Rett and Parkinsons. Will that be enough time...

I agree, AVXL's outperformance / value proposition becomes clearer with time. Shorter duration trials are likelier to be clouded by placebo effect. Many of these tests are subjective caregiver assessments. That's why Axovant had little chance for an adjunct with weak clinical effect no matter how much they powered it.
With Rett's kids' bodies are more germinal and hopefully any potential response will be rapid.